Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 8/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.33 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865716 | 0.89 | CDK9 (0.38) | CDK9BRD4ATAD2CCNT1 | |
| SCHEMBL17865681 | 0.85 | BRD4 (0.42) | HRH4CDK9BRD4ATAD2CCNT1 | |
| SCHEMBL3415446 | 0.75 | NPY5R (0.40) | BRD4ATAD2 | |
| SCHEMBL17865687 | 0.74 | BRD4 (0.40) | CDK9BRD4ATAD2CCNT1 | |
| SCHEMBL16525679 | 0.74 | TDO2 (0.36) | RIPK1TDO2KMT5BKMT5C | |
| SCHEMBL17865496 | 0.73 | HRH4 (0.42) | HRH4BRD4ATAD2TDO2 | |
| SCHEMBL17865651 | 0.73 | TDO2 (0.31) | HRH4RIPK1TDO2 | |
| SCHEMBL17865525 | 0.73 | F7 (0.41) | HRH4 | |
| SCHEMBL3014663 | 0.72 | BRD4 (0.43) | BRD4ATAD2 | |
| SCHEMBL3005194 | 0.72 | ADORA1 (0.45) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | claimed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | claimed |
| US-10927097-B2 | Indole compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2021-02-23 | — | — | US | disclosed |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | disclosed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927097-B2 | Indole compound as inhibitor of necrosis | IDO1, IDO2, TNF | HRH4 633/4885CDK9 799/4885BRD4 2391/4885 |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | HRH4 739/4885CDK9 683/4885BRD4 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.